Form 8-K

8-K — NANOVIRICIDES, INC.

Accession: 0001104659-26-111952

Filed: 2026-09-29

Period: 2026-09-28

CIK: 0001379006

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — tm2626486d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2626486d1_ex10-1.htm)

EX-10.2 — EXHIBIT 10.2 (tm2626486d1_ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2626486d1_8k.htm · Sequence: 1

false

0001379006

2026-09-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported)

September 28, 2026

NANOVIRICIDES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-36081

76-0674577

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

1 Controls Drive,

Shelton, Connecticut

06484

(Address of Principal Executive Offices)

(Zip Code)

(203) 937-6137

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s)

Name

of each exchange on which registered:

Common Stock,

NNVC

NYSE-American

Item 5.02.

Compensatory Arrangements of Certain Officers.

Extension Employment Agreement - Anil Diwan

On September 25, 2026, NanoViricides, Inc. (the

“Registrant”) entered into an Extension Agreement effective July 1, 2026 (the “Diwan Extension”) of the Employment

Agreement with Dr. Anil R. Diwan entered into on July 1, 2018 (the “Diwan Employment Agreement”) to continue to serve as the

President of the Registrant, effective July 1, 2026.

The Extension provides that Dr. Diwan will continue

to serve as the Registrant’s President until June 30, 2027 at a base annual base salary of $400,000. Dr. Diwan shall be entitled

to participate in all fringe benefits the Registrant provides for its employees generally and such other benefits as the Registrant provides

for its senior executives. In addition, the Registrant shall maintain a Term Life Insurance policy for Dr. Diwan, valued at $2 million,

of which $1 million shall be assigned to the Registrant and the remaining balance to Dr. Diwan’s estate.

In addition, as an incentive towards the ultimate

success of the Registrant, and to provide leadership authority to Dr. Diwan, the Registrant granted 10,204 shares of the Registrant’s

Series A Preferred Stock, par value $0.00001 per share to Dr. Diwan. Dr. Diwan’s rights in the shares shall vest in equal, quarterly

installments commencing on September 30, 2026 and fully vest on June 30, 2027. Dr. Diwan will be eligible to receive severance if he is

terminated by the Registrant other than for cause in which event the Registrant shall pay to Dr. Diwan an amount equal to six (6) month’s

salary as severance compensation (without regard to compensation or benefits Dr. Diwan receives from any other source). Dr. Diwan shall

be eligible for all benefits during this six (6) month period including bonuses, vesting of previously awarded stock options, health care

insurance and other fringe benefits that have been ongoing. The Registrant may elect to pay such severance compensation in a lump sum

or in equal payments over the six month period. A copy of the Diwan Extension is attached to this Form 8-K as Exhibit 10.1 and is incorporated

by reference.

Extension Employment Agreement - Meeta Vyas

On September 25, 2026, the Registrant) entered

into an Extension Agreement effective July 1, 2026 (the “Vyas Extension”) of the Employment

Agreement with Meeta Vyas of the Employment Agreement with Ms. Vyas entered into on May 31, 2013, (the “Vyas Employment Agreement”)

to continue to serve as the Chief Financial Officer of the Registrant, effective July 1, 2026.

The Vyas

Extension is renewable on an annual basis. The Vyas Employment Agreement provided for a term of three (3) years with a base compensation

of $9,000 per month and 129 shares of Series A preferred stock, also on a monthly basis. On January 1, 2015, her cash compensation was

increased to $10,800 per month. The Vyas Extension is for a period of one year from July 1, 2026 through June 30, 2027 under the same

general terms as the Vyas Employment Agreement with amendments to provide that the CFO shall be reimbursed up to 50% of all costs of Health

Insurance including any Medical, Dental, and any and all parts and subparts of Medicare Insurance that she subscribes to, not to exceed

$2,500 per month. A copy of the Vyas Extension is attached to this Form 8-K as Exhibit 10.2 and is incorporated by reference.

Item. 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1

Extension of Employment Agreement with Anil Diwan effective July 1, 2026

10.2

Extension of Employment Agreement with Meeta Vyas effective July 1, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES

EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

NANOVIRICIDES, INC.

Date: September 29, 2026

By:

/s/ Anil Diwan

Name: Anil Diwan

Title: President, Chairman

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2626486d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

EXTENSION TO EMPLOYMENT AGREEMENT

This Extension to Employment

Agreement (the “Extension”) effective as of July 1, 2026, between Anil R. Diwan, c/o NanoViricides, Inc., 1 Controls Drive,

Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484

(“the Company,” and collectively with the Employee, the “Parties”).

WHEREAS, the Parties

entered into that certain Employment Agreement on July 11, 2018 which was extended and expired pursuant to its terms on June 30, 2026

(the “Employment Agreement”);

WHEREAS, the parties

hereto desire to extend the term of the Employment Agreement and to add to and/or revise the terms and conditions of the Employment Agreement;

and

WHEREAS, the Parties

hereto desire that all other terms and conditions of the Employment Agreement not specifically amended hereby will remain in full force

and effect;

NOW THEREFORE, in consideration

of the foregoing and the mutual agreements set forth herein, and for good and valuable consideration, the receipt and sufficiency of which

are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

Term

The term of the Employment

Agreement shall be extended for an additional year beyond the previously extended Term and that Section 2 of the Employment Agreement

is amended by replacing Section 2 as follows:

The term of this Agreement

shall commence on July 1, 2026 and shall continue for one (1) year, i.e. ending June 30, 2027, but subject to the approval of the Board

of Directors, renewable annually thereafter upon approval of the Board of Directors, provided that either party can terminate the employment

at any time, for any reason, upon 30 days’ notice (the “Employment Period”).

Compensation and Benefits

Section 5 of the Employment

Agreement is amended by replacing Section 5 as follows:

The total compensation consists

of base salary, fringe benefits, stock awards, incentive awards, and performance bonuses as follows:

A. Base Salary and Fringe Benefits

As compensation for the Employee’s

services hereunder during the Employment Period, the Company shall pay the Employee a base salary of four hundred thousand ($400,000)

dollars per annum, commencing July 1, 2026, and through the effective period of the contract unless amended by the Compensation Committee.

Any base salary payable hereunder shall be paid in regular intervals in accordance with the Company’s payroll practices, but no

less frequently than once each month. The Employee shall be entitled to participate in all fringe benefits the Company provides for its

employees generally, and such other benefits as the Company provides generally for its senior executives. Such fringe benefits may include

paid time off (vacation and sick days), right to unpaid FMLA time off, medical insurance coverage (health, dental and vision), and Employee

Retirement Plan, as may exist from time to time. In addition, the Company shall maintain a Term Life Insurance policy for the Employee,

valued at $2 Million, of which $1 Million shall be assigned to the Company and remaining to the Employee’s Estate.

B. Grant of Series A Preferred

As an incentive towards the

ultimate success of the Company, and to provide leadership authority to the Executive, the Company grants 10,204 shares of the Company’s

Series A Convertible Preferred Stock, par value $0.00001 to Employee (the “Preferred Stock”) upon execution of this Agreement

(the “Grant Date”) and the Employee accepts such grant for itself and its successors and assigns, as follows:

i. Shareholder

Rights Pertaining to Granted Series A Preferred Shares

From and after the Grant Date,

Employee will be recorded as a shareholder of the Company with respect to the full amount of the Granted Series A Preferred Shares less

any Shares that are forfeited, transferred back to the Company or otherwise cancelled. Employee shall be entitled, from and after the

Grant Date, to vote the full amount of Granted Shares, whether vested or unvested, less any shares that are forfeited, transferred back

to the Company or otherwise cancelled.

ii. Transfer

Restrictions; Vesting

(a) Provided that the Employee

has not experienced a Termination of Service and remains continuously employed with the Company, the Employee’s rights in and to

the Shares shall be fully vested on June 30, 2027, and shall be deemed partially vested at 25% for each quarter in quarterly installments

following the Grant Date. Employee’s rights in and to the Shares shall be forfeitable unless and until otherwise vested pursuant

to the terms of this Extension.

Shares that have vested and

are no longer subject to forfeiture according to the above vesting schedule are referred to herein as “Vested Shares.”

Shares that have not vested and remain subject to forfeiture under the preceding schedule are referred to herein as “Unvested

Shares.”

(b) The vesting period and

the amount of the Award set forth above shall be adjusted on a prorated basis by the Board of Directors to reflect the decreased level

of employment during any period in which the Employee is on an approved leave of absence or is employed on a less than full time basis.

encumbrance, pledge, hypothecation, conveyance in trust, gift, transfer by bequest, devise or descent, or other transfer or disposition

of any kind, whether voluntary or by operation of law, directly or indirectly, of Unvested Shares shall be strictly prohibited and void;

provided, however, that the Board of Directors, in its sole discretion, may permit the Employee to assign or transfer an Award, provided

that the Award shall be subject to all the terms and condition of this Agreement and any other terms required by the Board of Directors

as a condition to such transfer.

iii. Forfeiture

upon Termination of Employment; Company Transaction

Upon a Termination of Service

for any reason, including without limitation, termination by the Company for Cause, voluntary resignation by the Employee or the Employee’s

death, Disability or Retirement, the Unvested Shares shall be forfeited by the Employee and cancelled and surrendered to the Company without

payment of any consideration to the Employee.

IN WITNESS

WHEREOF, the parties have executed this Agreement as of the date and year first written upon.

NANOVIRICIDES, INC.

EMPLOYEE

By:

/s/ Brian Zucker

/s/ Anil Diwan

Name: Brian Zucker

Anil Diwan

Title: Director

EX-10.2 — EXHIBIT 10.2

EX-10.2

Filename: tm2626486d1_ex10-2.htm · Sequence: 3

Exhibit 10.2

EXTENSION TO CHIEF FINANCIAL OFFICER EMPLOYMENT

AGREEMENT

This Extension to Employment

Agreement (the “Extension”) effective as of July 1, 2026, between MEETA VYAS, c/o NanoViricides, Inc., 1 Controls Drive, Shelton,

CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the

Company,” and collectively with the Employee, the “Parties”).

WHEREAS, the Parties

entered into that certain Employment Agreement on May 31, 2013, which as, extended, expired pursuant to its terms on June 30, 2026 (the

“CFO Employment Agreement”);

WHEREAS, the parties

hereto desire to extend the term of the CFO Employment Agreement and to add to and/or revise the terms and conditions of the CFO Employment

Agreement; and

WHEREAS, the Parties

hereto desire that all other terms and conditions of the CFO Employment Agreement not specifically amended hereby will remain in full

force and effect;

NOW THEREFORE, in consideration

of the foregoing and the mutual agreements set forth herein, and for good and valuable consideration, the receipt and sufficiency of which

are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

Term

The term of the CFO Employment

Agreement shall be extended for and additional year beyond the original Term and the CFO Employment Agreement is amended as follows:

The term of this Agreement shall

commence on July 1, 2026 and shall continue for one (1) year, i.e. ending June 30, 2027, but subject to the approval of the Board of Directors,

renewable annually thereafter upon approval of the Board of Directors, provided that either party can terminate the employment at any

time, for any reason, upon 30 days’ notice (the “Employment Period”).

IN WITNESS

WHEREOF, the parties have executed this Agreement as of the date and year first written upon.

NANOVIRICIDES, INC.

EMPLOYEE

By:

/s/ Brian Zucker

/s/ Meeta Vyas

Name: Brian Zucker

Meeta Vyas

Title: Director

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 28, 2026

Entity File Number

001-36081

Entity Registrant Name

NANOVIRICIDES, INC.

Entity Central Index Key

0001379006

Entity Tax Identification Number

76-0674577

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 Controls Drive

Entity Address, City or Town

Shelton

Entity Address, State or Province

Entity Address, Postal Zip Code

06484

City Area Code

203

Local Phone Number

937-6137

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock,

Trading Symbol

NNVC

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration